{"protocolSection":{"identificationModule":{"nctId":"NCT03880474","orgStudyIdInfo":{"id":"FLU009"},"organization":{"fullName":"Barinthus Biotherapeutics","class":"INDUSTRY"},"briefTitle":"Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults","officialTitle":"A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults Aged 18 Years and Over"},"statusModule":{"statusVerifiedDate":"2021-04","overallStatus":"TERMINATED","whyStopped":"The trial is being stopped for futility. Season 2 cancelled.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-03-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-10-15","type":"ACTUAL"},"completionDateStruct":{"date":"2020-01-21","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-21","studyFirstSubmitQcDate":"2019-03-14","studyFirstPostDateStruct":{"date":"2019-03-19","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-01-29","resultsFirstSubmitQcDate":"2021-04-23","resultsFirstPostDateStruct":{"date":"2021-04-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-04-23","lastUpdatePostDateStruct":{"date":"2021-04-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Barinthus Biotherapeutics","class":"INDUSTRY"},"collaborators":[{"name":"Clinical Network Services (CNS) Pty Ltd","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults","detailedDescription":"This is a Phase 2b, multicentre, randomised, single-blind study in up to 6000 adults to compare the efficacy, safety and immunogenicity of MVA-NP+M1 when given as an adjunct to a standard, licensed adult dose of QIV. The study will be conducted on an outpatient basis and will run over two consecutive influenza seasons. It is aimed to recruit 2200 participants in Season 1 and 2800-3800 participants in Season 2."},"conditionsModule":{"conditions":["Influenza"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":2364,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MVA-NP+M1","type":"EXPERIMENTAL","description":"Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu.)","interventionNames":["Biological: MVA-NP+M1"]},{"label":"Saline Placebo","type":"PLACEBO_COMPARATOR","description":"Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)","interventionNames":["Drug: Saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"MVA-NP+M1","description":"Trial Vaccine","armGroupLabels":["MVA-NP+M1"]},{"type":"DRUG","name":"Saline","description":"Sodium Chloride Placebo","armGroupLabels":["Saline Placebo"],"otherNames":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).","description":"The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza.\n\nIf influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset.\n\nThe incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019) in line with official Australian influenza season."}],"secondaryOutcomes":[{"measure":"Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary","description":"ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat.\n\nThe incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)"},{"measure":"Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)","description":"The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms.\n\nThe solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness).\n\nThe solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise.\n\nParticipants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study).\n\nThe participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group.\n\nDiary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.","timeFrame":"7 days to a total of 210 days for SAEs (over the duration of the influenza season, between 01 May and 15 October)"},{"measure":"Number of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)","description":"The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed.\n\nThe immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata).\n\nThe neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine.\n\nThe immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.","timeFrame":"Day 28 and Week 26"},{"measure":"Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary","description":"The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery).\n\nILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy.\n\nSurvival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)"},{"measure":"Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC","description":"The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \\[time in days\\])/(number of days used for analysis)) \\* 168","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)"},{"measure":"Number of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)","description":"The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed.\n\nThe immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted.\n\nThe immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.","timeFrame":"Day 28 and Week 26"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male or female adults aged 18 years and over\n* Receipt of a standard-dose licensed influenza QIV vaccine on the day of, or within 28 days prior to, randomisation\n* A female participant is eligible for this study if she is not pregnant or breast feeding and one of the following:\n\n  1. Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year)\n  2. Of childbearing potential but agrees to practice effective contraception 8 weeks post-vaccination and has a negative urine pregnancy test pre-vaccination. Acceptable methods of contraception include one or more of the following:\n\n  i. Male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for the female participant ii. Implants of levonorgestrel iii. Injectable progestogen iv. An intrauterine device with a documented failure rate of \\<1% v. Oral contraceptives vi. Double barrier methods including diaphragm or condom vii. Abstinence as long as it is line with the usual and preferred lifestyle of the participant\n* Participant is willing and has capacity to provide written informed consent for participation in the study (in the Investigator's opinion)\n* Able and willing (in the Investigator's opinion) to comply with all study requirements\n* Willing to allow the Investigators to discuss the participant's medical history with their healthcare provider\n* Present and able to visit the clinic in the event of an ILI episode during the influenza season\n\nExclusion Criteria:\n\n* Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigator, would either put the participant at risk because of participation in the study, or may influence the result of the study\n* Receipt of any investigational product within 6 months prior to study, or prior participation in a clinical study of any Influenza vaccine and agreement not to participate in another clinical study for the duration of study follow-up\n* Prior receipt of an investigational vaccine likely to impact on interpretation of the study data\n* Active infection with HIV, Hepatitis B or Hepatitis C (from patient history or medical records)\n* History of severe allergic reactions (e.g. anaphylaxis)\n* History of auto-immune disease e.g. Guillain-Barré syndrome\n* Not willing to comply with study procedures\n* Immunosuppressed or taking immunosuppressive medications\n* Use of warfarin or other blood thinning medications (aspirin is acceptable)\n* Tattoos or birthmarks at the vaccination site\n* Participant bruises easily, has haematoma or keloid scarring\n* Receipt of a licenced inactivated vaccine (e.g. pneumococcal vaccine) within 2 weeks prior to vaccination\n* Receipt of an off licensed live vaccine (e.g. herpes zoster vaccine) within 4 weeks prior to vaccination","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"James Vandeleur, MD","affiliation":"Paratus Clinical Pty Ltd","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Paratus Clinical Pty Ltd","city":"Blacktown","state":"New South Wales","zip":"2148","country":"Australia","geoPoint":{"lat":-33.76667,"lon":150.91667}},{"facility":"Genesis Research Services","city":"Broadmeadow","state":"New South Wales","zip":"2292","country":"Australia","geoPoint":{"lat":-32.92371,"lon":151.72849}},{"facility":"Paratus Clinical Pty Ltd","city":"Kanwal","state":"New South Wales","zip":"2259","country":"Australia","geoPoint":{"lat":-33.253,"lon":151.4911}},{"facility":"Scientia Clinical Research","city":"Sydney","state":"New South Wales","zip":"2031","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"University of Sunshine Coast (USC)","city":"Morayfield","state":"Queensland","zip":"4506","country":"Australia","geoPoint":{"lat":-27.10876,"lon":152.94907}},{"facility":"University of Sunshine Coast (USC)","city":"Sippy Downs","state":"Queensland","zip":"4556","country":"Australia","geoPoint":{"lat":-26.71793,"lon":153.05475}},{"facility":"Mater Research","city":"South Brisbane","state":"Queensland","zip":"4101","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"CMAX","city":"Adelaide","state":"South Australia","zip":"5000","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Nucleus Network Pty Ltd","city":"Melbourne","state":"Victoria","zip":"3004","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}}]},"referencesModule":{"references":[{"pmid":"35305317","type":"DERIVED","citation":"Evans TG, Bussey L, Eagling-Vose E, Rutkowski K, Ellis C, Argent C, Griffin P, Kim J, Thackwray S, Shakib S, Doughty J, Gillies J, Wu J, Druce J, Pryor M, Gilbert S. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. Lancet Infect Dis. 2022 Jun;22(6):857-866. doi: 10.1016/S1473-3099(21)00702-7. Epub 2022 Mar 16."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"2364 were screened and 2152 participants started randomized in a 1:1 ratio and received (along with a licensed adult dose of QIV), either active drug (MVA-NP+M1) or Placebo, via IM injection. Overall, 1077 participants received active drug and 1075 Placebo. A total of 2109 participants completed the study. The Immunogenicity Cohort was a subset of 50 participants: 25 participants were administered active drug and 25 participants were administered Placebo. All 50 participants completed the study.","recruitmentDetails":"The single-blind study was conducted at 9 sites across Australia, over one Influenza season.","groups":[{"id":"FG000","title":"MVA-NP+M1 Group (Main Cohort + Immunogenicity Cohort)","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"FG001","title":"Saline Placebo Group (Main Cohort+ Immunogenicity Cohort)","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1077"},{"groupId":"FG001","numSubjects":"1075"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1054"},{"groupId":"FG001","numSubjects":"1055"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"20"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"BG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1077"},{"groupId":"BG001","value":"1075"},{"groupId":"BG002","value":"2152"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43.6","spread":"18.93"},{"groupId":"BG001","value":"43.8","spread":"18.40"},{"groupId":"BG002","value":"43.7","spread":"18.66"}]}]}]},{"title":"Sex/Gender, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Female","categories":[{"measurements":[{"groupId":"BG000","value":"631"},{"groupId":"BG001","value":"631"},{"groupId":"BG002","value":"1262"}]}]},{"title":"Male","categories":[{"measurements":[{"groupId":"BG000","value":"445"},{"groupId":"BG001","value":"443"},{"groupId":"BG002","value":"888"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1061"},{"groupId":"BG001","value":"1052"},{"groupId":"BG002","value":"2113"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"18"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"143"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"261"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"21"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"16"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"882"},{"groupId":"BG001","value":"892"},{"groupId":"BG002","value":"1774"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"71"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28.36","spread":"6.727"},{"groupId":"BG001","value":"28.26","spread":"6.143"},{"groupId":"BG002","value":"28.31","spread":"6.435"}]}]}]},{"title":"Body Temperature","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"degree Celsius","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36.44","spread":"0.420"},{"groupId":"BG001","value":"36.44","spread":"0.401"},{"groupId":"BG002","value":"36.44","spread":"0.410"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).","description":"The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza.\n\nIf influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset.\n\nThe incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019) in line with official Australian influenza season.","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1077"},{"groupId":"OG001","value":"1075"}]}],"classes":[{"categories":[{"title":"Participants with laboratory confirmed influenza using RT-PCR","measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"23"}]},{"title":"Participants without laboratory confirmed influenza using RT-PCR","measurements":[{"groupId":"OG000","value":"1042"},{"groupId":"OG001","value":"1052"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.1146","statisticalMethod":"Log Binominal Model","paramType":"Relative Risk","paramValue":"1.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"2.55"},{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.1146","statisticalMethod":"Poisson Model with Robust Variance","paramType":"Relative Risk","paramValue":"1.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"2.55"}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary","description":"ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat.\n\nThe incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1077"},{"groupId":"OG001","value":"1075"}]}],"classes":[{"categories":[{"title":"Positive ILI Cases","measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"273"}]},{"title":"Negative ILI Cases","measurements":[{"groupId":"OG000","value":"804"},{"groupId":"OG001","value":"802"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The Analysis concerns the Incidence of Influenza-like Illness (ILI)","nonInferiorityType":"OTHER","pValue":"1.0000","statisticalMethod":"Log Binomial Model","paramType":"Relative Risk","paramValue":"1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.15"},{"groupIds":["OG000","OG001"],"groupDescription":"The Analysis concerns the Incidence of Influenza-like Illness (ILI)","nonInferiorityType":"OTHER","pValue":"0.9799","statisticalMethod":"Poisson Model with Robust Variance","paramType":"Relative Risk","paramValue":"1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.15"}]},{"type":"SECONDARY","title":"Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)","description":"The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms.\n\nThe solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness).\n\nThe solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise.\n\nParticipants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study).\n\nThe participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group.\n\nDiary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.","populationDescription":"Safety Analysis Set","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"7 days to a total of 210 days for SAEs (over the duration of the influenza season, between 01 May and 15 October)","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1077"},{"groupId":"OG001","value":"1075"}]}],"classes":[{"title":"Participants with Solicited Local Injection Site Reaction (IRS) - Pain","categories":[{"measurements":[{"groupId":"OG000","value":"292"},{"groupId":"OG001","value":"19"}]}]},{"title":"Participants with Solicited Local Injection Site Reaction (IRS) - Induration","categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"4"}]}]},{"title":"Participants with Solicited Local Injection Site Reaction (IRS) - Warmth","categories":[{"measurements":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"18"}]}]},{"title":"Participants with Solicited Local Injection Site Reaction (IRS) - Erythema","categories":[{"measurements":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"15"}]}]},{"title":"Participants with Severe, Solicited Local Injection Site Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"1"}]}]},{"title":"Participants with Solicited Systemic Reactions - Chills","categories":[{"measurements":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"18"}]}]},{"title":"Participants with Solicited Systemic Reactions - Myalgia","categories":[{"measurements":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"85"}]}]},{"title":"Participants with Solicited Systemic Reactions - Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"117"}]}]},{"title":"Participants with Solicited Systemic Reactions - Headache","categories":[{"measurements":[{"groupId":"OG000","value":"238"},{"groupId":"OG001","value":"106"}]}]},{"title":"Participants with Solicited Systemic Reactions - Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"31"}]}]},{"title":"Participants with Solicited Systemic Reactions - Arthralgia","categories":[{"measurements":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"57"}]}]},{"title":"Participants with Solicited Systemic Reactions - Malaise","categories":[{"measurements":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"139"}]}]},{"title":"Participants with Solicited Systemic Reactions - Feverishness","categories":[{"measurements":[{"groupId":"OG000","value":"214"},{"groupId":"OG001","value":"93"}]}]},{"title":"Participants with Severe, Solicited Systemic Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"14"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)","description":"The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed.\n\nThe immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata).\n\nThe neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine.\n\nThe immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.","populationDescription":"The samples for immunogenicity analysis were taken only from participants in the 2 Immunogenicity cohorts included in the MVA-NP+M1 Group vs the Placebo Group.\n\nThe immunogenicity analysis for Day 28 used a number of 24 participant results from the MVA-NP+M1 Cohort and a number of 24 participant results from the Placebo Cohort.\n\nThe immunogenicity analysis for Week26 used a number of 23 participant results from the MVA-NP+M1 Cohort and a number of 25 participant results from the Placebo Cohort.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 28 and Week 26","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"}]}]},{"title":"Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H3N2 (HI) at Day 28","nonInferiorityType":"OTHER","pValue":"0.3284","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"-287.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-872.75","ciUpperLimit":"298.59"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H3N2 (HI) at Week26","nonInferiorityType":"OTHER","pValue":"0.8468","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"-13.39","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-152.26","ciUpperLimit":"125.47"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H3N2 (MN) at Day 28","nonInferiorityType":"OTHER","pValue":"0.5087","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"-465.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1875.21","ciUpperLimit":"943.75"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H3N2 (MN) at Week 26","nonInferiorityType":"OTHER","pValue":"0.7509","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"-83.68","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-611.67","ciUpperLimit":"444.32"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H1N1pdm at Day 28","nonInferiorityType":"OTHER","pValue":"0.3398","statisticalMethod":"ANOVA","paramType":"Least Squares Mean Difference","paramValue":"-81.17","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-250.72","ciUpperLimit":"88.39"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza A/H1N1pdm at Week 26","nonInferiorityType":"OTHER","pValue":"0.4154","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"26.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-37.95","ciUpperLimit":"90.26"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of neutralizing antibodies against Influenza B/ Victoria at Day 28","nonInferiorityType":"OTHER","pValue":"0.7193","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"22.84","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-104.50","ciUpperLimit":"150.18"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza B/ Victoria at Week 26","nonInferiorityType":"OTHER","pValue":"0.1496","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"52.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.59","ciUpperLimit":"124.35"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza B/Yamagata at Day 28","nonInferiorityType":"OTHER","pValue":"0.9044","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"-16.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-296.57","ciUpperLimit":"263.06"},{"groupIds":["OG000","OG001"],"groupDescription":"Titers of influenza-specific neutralizing antibodies against Influenza B/Yamagata at Week 26","nonInferiorityType":"OTHER","pValue":"0.4198","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"38.64","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-56.97","ciUpperLimit":"134.24"}]},{"type":"SECONDARY","title":"Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary","description":"The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery).\n\nILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy.\n\nSurvival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.","populationDescription":"ILI duration analysis is only applicable for ILI positive participants. In the MVA-NP+M1 Group there were 273 ILI positive participants assessed: 247 with event and 26 censored; In the Placebo Group there were 273 ILI positive participants assessed: 248 with event and 25 censored.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"days","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"273"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","lowerLimit":"3","upperLimit":"4"},{"groupId":"OG001","value":"3","lowerLimit":"3","upperLimit":"4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.4159","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"1.08","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.90","ciUpperLimit":"1.28"}]},{"type":"SECONDARY","title":"Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC","description":"The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \\[time in days\\])/(number of days used for analysis)) \\* 168","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"weighted days","timeFrame":"210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1077"},{"groupId":"OG001","value":"1075"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5490","spread":"23.4944"},{"groupId":"OG001","value":"5297","spread":"21.3996"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Feeling Hot (AUC)","nonInferiorityType":"OTHER","pValue":"0.9550","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.83","ciUpperLimit":"1.19"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Temperature (AUC)","nonInferiorityType":"OTHER","pValue":"0.8933","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1","ciUpperLimit":"1"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Cough (AUC)","nonInferiorityType":"OTHER","pValue":"0.2156","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.7","ciUpperLimit":"1.09"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Sore Throat AUC","nonInferiorityType":"OTHER","pValue":"0.2216","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.10"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Blocked Nose AUC","nonInferiorityType":"OTHER","pValue":"0.2306","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.69","ciUpperLimit":"1.09"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Chest Pain AUC","nonInferiorityType":"OTHER","pValue":"0.8038","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.97","ciUpperLimit":"1.13"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Muscle Pain AUC","nonInferiorityType":"OTHER","pValue":"0.9319","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.21"},{"groupIds":["OG000","OG001"],"groupDescription":"Time Weight Area Under the Curve (AUC) for Symptoms of Influenza - Symptom: Shortness of Breath AUC","nonInferiorityType":"OTHER","pValue":"0.8399","statisticalMethod":"ANOVA","paramType":"Geometric Mean Ratio (Active vs Placebo)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.86","ciUpperLimit":"1.19"}]},{"type":"SECONDARY","title":"Number of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)","description":"The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed.\n\nThe immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted.\n\nThe immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.","populationDescription":"The samples for this immunogenicity analysis were taken only from participants in the 2 Immunogenicity cohorts included in the MVA-NP+M1 Group vs the Placebo Group.\n\nThe immunogenicity analysis for Day 28 used 24 participant results from the MVA-NP+M1 Cohort and 24 participant results from the Placebo Cohort, as available.\n\nThe immunogenicity analysis for Week26 used 23 participant results from the MVA-NP+M1 Cohort and 25 participant results from the Placebo Cohort, as available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 28 and Week 26","groups":[{"id":"OG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."},{"id":"OG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"25"}]}],"classes":[{"title":"Participants with immunogenic response (as the frequency of influenza-specific T-cells) at Day 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"21"}]}]},{"title":"Participants with Immunogenic response (via the frequency of influenza-specific T-cells) at Week 26","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis was performed for Total(NP+M) (SFU/10\\^6 PBMC) at Day 28 Nucleoprotein = NP, matrix1 = M1","nonInferiorityType":"OTHER","pValue":"0","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"743.78","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"443.71","ciUpperLimit":"1043.84"},{"groupIds":["OG000","OG001"],"groupDescription":"Statistical analysis was performed for Total(NP+M) (SFU/10\\^6 PBMC) at Week 26 Nucleoprotein = NP, matrix1 = M1","nonInferiorityType":"OTHER","pValue":"0.0673","statisticalMethod":"ANCOVA","paramType":"Least Squares Mean Difference","paramValue":"177.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-13.14","ciUpperLimit":"367.33"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Unsolicited non-serious adverse events will be collected for 28 days post-vaccination. Hospitalisations, other serious adverse events and or adverse events of special interest will be collected for the duration of the influenza season. Solicited adverse events, including solicited local injection site reactions (ISR) and solicited systemic reactions, will be collected for 7 days post-vaccination. These will be recorded daily in the eDiary for all participants.","description":"Adverse events were coded using MedDRA(most recent version). AEs are grouped by system organ class (SOC) and preferred term and summarized by vaccination group (MVA-NP+M1 Group vs Saline Placebo Group) at the time of AE onset. All AEs are reported for each group and the Immunogenicity cohorts (as parts of each group) did not influence the adverse events reporting style.\n\nIn the summary tables, adverse events are presented/summarized by decreasing frequency of Total Events overall within each SOC","eventGroups":[{"id":"EG000","title":"MVA-NP+M1 Group","description":"Vaccination administered: 1 dose of MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\\^8 pfu per dose) MVA-NP+M1: Trial Vaccine Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the MVA-NP+M1 group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected.","deathsNumAffected":0,"deathsNumAtRisk":1077,"seriousNumAffected":18,"seriousNumAtRisk":1077,"otherNumAffected":524,"otherNumAtRisk":1077},{"id":"EG001","title":"Saline Placebo Group","description":"Vaccination administered: 1 dose of Sodium Chloride (IM injection, 0.5 ml, 0.9% per dose) Saline: Sodium Chloride Placebo Vaccinations were administered by intramuscular injection on Day 0. The participants were provided with an oral thermometer, tape measure and electronic diary card (eDiary) and instructed how to complete the eDiary at home.\n\nParticipants recorded their oral temperature and any solicited adverse events for 7 days post-vaccination and unsolicited adverse events for 28 days post-vaccination.\n\nThe study team contacted participants by telephone on Day 1 (+2 days) post-vaccination and Day 7 (+3 days) post-vaccination for safety follow-up. If the participant had persistent, vaccine-related Grade 3 AEs during the first 4 weeks post-vaccination they could be asked to attend a further clinical assessment.\n\nThe Immunogenicity Cohort of the Placebo group (25 participants), had pre vaccination safety laboratory and immunogenicity blood samples taken.\n\nIn addition to the visits and procedures outlined above these participants attended an additional three clinic visits on Days 7 (+3 days), 28 (±7 days) and Week 26 (±1 week) (approximate end of the influenza season).\n\nAt the end of the influenza season, all participants were contacted by telephone to inform them of the end of the follow-up period and confirm all information had been collected.","deathsNumAffected":1,"deathsNumAtRisk":1075,"seriousNumAffected":22,"seriousNumAtRisk":1075,"otherNumAffected":435,"otherNumAtRisk":1075}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":1077},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":1075}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numAffected":1,"numAtRisk":1075}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Infective exacerbation of chronic obstructive airways disease","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Lower respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Medical device site joint infection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Pneumonia mycoplasmal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":1075}]},{"term":"COPD","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Bronchial hyperreactivity","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Bronchiectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Skin laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Cholecystectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Endometriosis ablation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Hysterectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Bipolar disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Adnexal torsion","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Arthritis reactive","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":1075}]}],"otherEvents":[{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":122,"numAffected":115,"numAtRisk":1077},{"groupId":"EG001","numEvents":127,"numAffected":119,"numAtRisk":1075}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":97,"numAffected":89,"numAtRisk":1077},{"groupId":"EG001","numEvents":102,"numAffected":93,"numAtRisk":1075}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":95,"numAffected":90,"numAtRisk":1077},{"groupId":"EG001","numEvents":93,"numAffected":84,"numAtRisk":1075}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":76,"numAffected":73,"numAtRisk":1077},{"groupId":"EG001","numEvents":91,"numAffected":86,"numAtRisk":1075}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":25,"numAtRisk":1077},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":1075}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":170,"numAffected":145,"numAtRisk":1077},{"groupId":"EG001","numEvents":135,"numAffected":122,"numAtRisk":1075}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":15,"numAffected":12,"numAtRisk":1075}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":74,"numAffected":73,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":43,"numAtRisk":1077},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":1075}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":30,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":1077},{"groupId":"EG001","numEvents":21,"numAffected":19,"numAtRisk":1075}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":1077},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":1075}]},{"term":"Feeling hot","organSystem":"General disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":59,"numAtRisk":1077},{"groupId":"EG001","numEvents":39,"numAffected":36,"numAtRisk":1075}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1077},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":1075}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":1075}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":1077},{"groupId":"EG001","numEvents":34,"numAffected":31,"numAtRisk":1075}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1077},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":1075}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":1077},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":1075}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":26,"numAtRisk":1077},{"groupId":"EG001","numEvents":26,"numAffected":24,"numAtRisk":1075}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":1077},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":1075}]},{"term":"INJURY, POISONING AND PROCEDURAL COMPLICATIONS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":1077},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":1075}]},{"term":"SKIN AND SUBCUTANEOUS TISSUE DISORDERS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":19,"numAtRisk":1077},{"groupId":"EG001","numEvents":19,"numAffected":18,"numAtRisk":1075}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":1077},{"groupId":"EG001","numEvents":14,"numAffected":12,"numAtRisk":1075}]},{"term":"EAR AND LABYRINTH DISORDERS","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":1077},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":1075}]},{"term":"EYE DISORDERS","organSystem":"Eye disorders","sourceVocabulary":"MedDRA (20.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":1077},{"groupId":"EG001","numEvents":16,"numAffected":14,"numAtRisk":1075}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Tom Evans, MD","organization":"Vaccitech Ltd.","email":"enquiries@vaccitech.co.uk","phone":"+44 01865 591 445"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-05-20","uploadDate":"2021-01-29T04:44","filename":"Prot_000.pdf","size":1430612},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-01-01","uploadDate":"2021-01-29T05:49","filename":"SAP_001.pdf","size":935668}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}